Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical Conference
CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in […]